Clinical Trials Logo

Recurrent Thyroid Gland Carcinoma clinical trials

View clinical trials related to Recurrent Thyroid Gland Carcinoma.

Filter by:

NCT ID: NCT02973997 Not yet recruiting - Clinical trials for Recurrent Thyroid Gland Carcinoma

Pembrolizumab and Lenvatinib in Treating Metastatic or Recurrent Differentiated Thyroid Cancer That Cannot Be Removed by Surgery

Start date: April 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pembrolizumab and lenvatinib work in treating patients with differentiated thyroid cancer that has spread to other places in the body or has come back and cannot be removed by surgery. Monoclonal antibodies, such as pembrolizumab and kinase inhibitors, such as lenvatinib, may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT02465060 Recruiting - Lymphoma Clinical Trials

NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma

Start date: August 12, 2015
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.

NCT ID: NCT02393690 Recruiting - Clinical trials for Recurrent Thyroid Gland Carcinoma

Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer

Start date: May 4, 2015
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well iodine I-131 works with or without selumetinib in treating patients with thyroid cancer that has returned or has spread from where it started to other places in the body. Many thyroid cancers absorb iodine. Because of this, doctors often give radioactive iodine (iodine I-131) alone to treat thyroid cancer as part of standard practice. It is thought that the more thyroid tumors are able to absorb radioactive iodine, the more likely it is that the radioactive iodine will cause those tumors to shrink. Selumetinib may help radioactive iodine work better in patients whose tumors still absorb radioactive iodine. It is not yet known whether iodine I-131 is more effective with or without selumetinib in treating thyroid cancer.

NCT ID: NCT02152995 Recruiting - Clinical trials for Recurrent Thyroid Gland Carcinoma

Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

Start date: August 14, 2014
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well trametinib works in increasing tumoral iodine incorporation in patients with thyroid cancer that has come back or spread to another place in the body. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may help make treatment with iodine I-131 more effective.

NCT ID: NCT01811212 Active, not recruiting - Clinical trials for Recurrent Thyroid Gland Carcinoma

Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer

Start date: May 8, 2013
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well cabozantinib-s-malate works in treating patients with thyroid cancer that does not respond to treatment. Cabozantinib-s-malate may stop the growth of thyroid cancer by blocking some of the enzymes needed for cell growth. Cabozantinib-s-malate may also stop the growth of thyroid cancer by blocking blood flow to the tumor.

NCT ID: NCT01709435 Active, not recruiting - Recurrent Melanoma Clinical Trials

Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors

Start date: November 14, 2012
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of cabozantinib S-malate in treating younger patients with solid tumors that have come back or no longer respond to treatment. Cabozantinib S-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01638533 Recruiting - Lymphoma Clinical Trials

Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction

Start date: June 12, 2012
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of romidepsin in treating patients with lymphoma, chronic lymphocytic leukemia, or solid tumors with liver dysfunction. Romidepsin may stop the growth of cancer cells by entering the cancer cells and by blocking the activity of proteins that are important for the cancer's growth and survival.

NCT ID: NCT01208051 Active, not recruiting - Clinical trials for Recurrent Thyroid Gland Carcinoma

Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer

Start date: September 9, 2010
Phase: Phase 1/Phase 2
Study type: Interventional

This partially randomized phase I/II trial studies the side effects and best dose of cediranib maleate when given together with or without lenalidomide and to see how well they work in treating patients with thyroid cancer. Cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Lenalidomide may stop the growth of thyroid cancer by blocking blood flow to the tumor. It is not yet known whether cediranib maleate is more effective when given together with lenalidomide in treating thyroid cancer.

NCT ID: NCT00729157 Completed - Clinical trials for Recurrent Thyroid Gland Carcinoma

Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy

Start date: August 2008
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well aflibercept works in treating patients with recurrent and/or metastatic thyroid cancer that has not responded to radioactive iodine therapy. Aflibercept may stop the growth of tumor cells by blocking blood flow to the tumor and by carrying tumor-killing substances directly to thyroid cancer cells.

NCT ID: NCT00625846 Active, not recruiting - Clinical trials for Recurrent Thyroid Gland Carcinoma

Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer

Start date: February 22, 2008
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects and how well pazopanib hydrochloride works in treating patients with advanced thyroid cancer. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by stopping blood flow to the tumor.